NCT02601027

Brief Summary

The primary objective is to determine if pre-operative transversus abdominis plane (TAP) nerve blocks by continued infusion of local anesthetic post-operatively affects post-operative narcotic usage, as compared to a placebo TAP block, after breast reconstruction surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Nov 2015

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

November 4, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 10, 2015

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 7, 2019

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
4 months until next milestone

Results Posted

Study results publicly available

September 23, 2021

Completed
Last Updated

September 23, 2021

Status Verified

August 1, 2021

Enrollment Period

3.9 years

First QC Date

November 4, 2015

Results QC Date

June 28, 2021

Last Update Submit

August 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Post-operative Narcotic Usage

    Narcotic usage was collected for first 48 hours post-operatively after breast reconstruction. The type and amount of each narcotic administered were each converted to the morphine equivalent amount that would be orally administered to achieve the same event. This term is known as the oral morphine equivalent (OME). Narcotic usage was assessed between the group receiving transversus abdominis plane (TAP) nerve block compared to the group receiving the placebo control. The outcome is reported as the observed OME for each group.

    48 hours

Secondary Outcomes (5)

  • Post-operative Pain Score

    2 days

  • Post-operative Anti-emetic Usage

    48 hours

  • Time to Ambulation

    up to 1 week

  • Time to First Bowel Movement

    up to 1 week

  • Quality of Life Measurement

    Pre-operative Baseline and Post-operative (2-6 months)

Study Arms (2)

0.125% Bupivacaine

EXPERIMENTAL

0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter

Procedure: Transversus Abdominis Plane (TAP) blockDevice: Nimbus Infusion Pump IV AdministrationDrug: Bupivacaine infusionDrug: AcetominophenDrug: HydromorphoneDrug: OxycodoneDrug: Ondansetron

Placebo

PLACEBO COMPARATOR

Saline infusion (sham) via transversus abdominis plane (TAP) catheter.

Procedure: Transversus Abdominis Plane (TAP) blockDevice: Nimbus Infusion Pump IV AdministrationDrug: AcetominophenDrug: HydromorphoneDrug: OxycodoneDrug: Ondansetron

Interventions

0.125% BupivacainePlacebo
0.125% BupivacainePlacebo
Also known as: Exparel, Marcaine, Marcaine Spinal, Sensorcaine, Sensorcaine-MPF, Sensorcaine-MPF Spinal, ReadySharp bupivacaine, P-Care M
0.125% Bupivacaine
Also known as: Tylenol
0.125% BupivacainePlacebo
Also known as: Dilaudid, Dilaudid-HP, Exalgo
0.125% BupivacainePlacebo
Also known as: Oxycontin, Xtampza ER, Oxaydo, Roxicodone
0.125% BupivacainePlacebo
Also known as: Zofran, Zofran ODT, Zuplenz
0.125% BupivacainePlacebo

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Prior diagnosis or presumed diagnosis of breast cancer or undergoing prophylactic treatment.
  • Greater than 18 years old.
  • Female.
  • Undergoing microsurgical breast reconstruction with abdominal free flap.
  • Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if:

  • True allergy to local anesthetics or opioids.
  • History of addiction to narcotics within the last 24 months
  • History of chronic pain on opioids within the last 24 months.
  • Specific mental health issues such as schizophrenia or bipolar disorder.
  • Patients who are pregnant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University Medical Center

Stanford, California, 94305, United States

Location

Related Publications (4)

  • Mundy LR, Homa K, Klassen AF, Pusic AL, Kerrigan CL. Breast Cancer and Reconstruction: Normative Data for Interpreting the BREAST-Q. Plast Reconstr Surg. 2017 May;139(5):1046e-1055e. doi: 10.1097/PRS.0000000000003241.

    PMID: 28445351BACKGROUND
  • Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009 Aug;124(2):345-353. doi: 10.1097/PRS.0b013e3181aee807.

    PMID: 19644246BACKGROUND
  • Voineskos SH, Klassen AF, Cano SJ, Pusic AL, Gibbons CJ. Giving Meaning to Differences in BREAST-Q Scores: Minimal Important Difference for Breast Reconstruction Patients. Plast Reconstr Surg. 2020 Jan;145(1):11e-20e. doi: 10.1097/PRS.0000000000006317.

    PMID: 31577663BACKGROUND
  • Kwong JW, Tijerina JD, Choi S, Shakir A, Nguyen DH, Nazerali RS, Lee GK. Randomized Double-Blinded, Placebo-Controlled Trial: Transversus Abdominis Plane (TAP) Blocks in Breast Cancer Patients Undergoing Reconstruction with Abdominal Free Flap. Annual Meeting of the California Society of Plastic Surgeons. San Diego, California. May 19, 2018.

    RESULT

MeSH Terms

Interventions

Dental OcclusionBupivacaineAcetaminophenHydromorphoneOxycodoneOndansetron

Intervention Hierarchy (Ancestors)

DentistryDental Physiological PhenomenaDigestive System and Oral Physiological PhenomenaAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesAcetanilidesMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsCodeineImidazolesAzolesHeterocyclic Compounds, 1-RingCarbazolesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, 3-Ring

Results Point of Contact

Title
Gordon Kwanlyp Lee, Professor of Surgery (Plastic and Reconstructive Surgery)
Organization
Stanford University

Study Officials

  • Gordon K Lee, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Surgery (Plastic and Reconstructive Surgery)

Study Record Dates

First Submitted

November 4, 2015

First Posted

November 10, 2015

Study Start

November 1, 2015

Primary Completion

September 7, 2019

Study Completion

June 1, 2021

Last Updated

September 23, 2021

Results First Posted

September 23, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations